Over the last several years, we have come to recognize that healthy individuals often harbor somatic alterations which are detectable in the peripheral blood but are not specifically diagnostic for a hematologic neoplasm and has been named Clonal Hematopoiesis (CH). In addition, some patients show evidence of clonal hematopoiesis and a cytopenia but no overt evidence of morphologic dysplasia. This session aims to review our understanding of the impact of CH on health and how the presence of multiple clonal mutations may impact diagnosis of a hematologic neoplasm.
How Do I Manage a Patient with CH?
Kelly Bolton, MD PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
How Can I Use Mutation Data to Diagnose MDS in a Patient with Cytopenia and No Morphologic
Dysplasia?
Amy E. Dezern, MD, MHS, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Objectives:
- Understand the effects of CH on health and clinical management strategies.
- Review, in the context of unexplained cytopenia, the diagnostic value of a somatic mutation analysis.
Recording Date: November 19, 2020
Continuing Education Credit Information
CME/CMLE credit: 1.50 hr
Last day to purchase course and CE claim credit: February 16, 2024
Note: Members of AMP can access this at a discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
